Listed by the USPTO as GONZALEZ, LUISALBERTO
Tech Center 1600 • Art Units: 1624 1626 1632
This examiner grants 58% of resolved cases
GONZALEZ, LUISALBERTO is assigned to tech center 1600 and art unit 1624. The profile includes 168 resolved cases, with an allowance rate of 58.3% and a median of 1077 days to allowance. The interview lift is 47.6%, making interview activity a substantial part of the recorded outcome pattern.
The leading companies are Orcosa Inc., Syngenta AG, and Yale University. The top firms are PATTERSON + SHERIDAN, L.L.P., BakerHostetler, and Dentons US LLP. Practitioners may give interviews focused attention when developing a prosecution plan, while using the allowance and timing figures to establish broad historical expectations.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18953295 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | Non-Final OA | Merck Patent GmbH |
| 18575717 | USE OF FLUAZIFOP-P-BUTYL FOR INSECT CONTROL | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18552055 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 19347194 | METHODS FOR TREATING ALZHEIMER DISEASE AND FOR REDUCING AMYLOID BETA FORMATION | Final Rejection | SK CHEMICALS Co., Ltd. |
| 18711747 | COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG | Non-Final OA | Shionogi & Co., Ltd. |
| 18934169 | COMPOUNDS AND METHODS FOR USING GALLOYLATED POLYPHENOLS TO TREAT DISEASES MEDIATED BY THIOL ISOMERASES | Non-Final OA | Beth Israel Deaconess Medical Center, Inc. |
| 18703125 | COMPOSITIONS AND METHODS FOR TARGETING GPCR FOR THE PREVENTION AND TREATMENT OF PAIN | Non-Final OA | Duke University |
| 18683106 | COMPOSITIONS FOR ORGAN AND TISSUE PRESERVATION | Non-Final OA | Yale University |
| 18571471 | ANTI-CANCER COMPOUNDS AND METHODS OF USE | Final Rejection | YALE UNIVERSITY |
| 18611505 | Substituted Bimane Compounds and Methods of Use Thereof | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17359714 | MODIFIED RELEASE FORMULATIONS OF MODIFIED FORMS OF TRIMETAZIDINE | Non-Final OA | IMBRIA PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy58.3% of resolved applications examined by Luisalberto Gonzalez were allowed (168 resolved cases), compared with 54.4% across Art Unit 1624 over the last five years.
This examiner's interview lift is +47.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Luisalberto Gonzalez took 1,077 days on average from filing to allowance.
Luisalberto Gonzalez examines applications in Art Unit 1624 in Tech Center 1600 (Biotechnology & Pharmaceuticals).